August 2009 Volume 5 Number 8
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=34&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Rheumatology online. To purchase a subscription, please
visit: http://links.ealert.nature.com/ctt?kn=19&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=37&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 5.677*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
The Number 1 monthly review journal in Rheumatology
We are delighted to announce Nature Reviews Rheumatology's (previously
Nature Clinical Practice Rheumatology) new Impact Factor is 5.677* and
it is ranked 3/22 in Rheumatology.
http://links.ealert.nature.com/ctt?kn=99&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
*2008 Journal Citation Report (Thomson Reuters, 2009) Nature Reviews
Rheumatology was previously published as Nature Clinical Practice
Rheumatology.
=====================================================================
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
----------------------
RESEARCH HIGHLIGHTS
----------------------
Osteoarthritis: Targeting cathepsin K to prevent cartilage loss: evidence
from a dog model of OA
p411 | doi:10.1038/nrrheum.2009.113
http://links.ealert.nature.com/ctt?kn=106&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Surgery: Benefits of rheumatoid hand arthroplasty after 1 year
p412 | doi:10.1038/nrrheum.2009.124
http://links.ealert.nature.com/ctt?kn=102&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Osteoimmunology: Unexpected effects of NF[kappa]B in bone formation
p412 | doi:10.1038/nrrheum.2009.130
http://links.ealert.nature.com/ctt?kn=94&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Inflammatory myopathies: Sustaining remission in juvenile dermatomyositis
p413 | doi:10.1038/nrrheum.2009.123
http://links.ealert.nature.com/ctt?kn=2&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Bone: Osteoclastogenesis inhibitor identified
p413 | doi:10.1038/nrrheum.2009.128
http://links.ealert.nature.com/ctt?kn=77&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Neutrophil nets in SVV pathogenesis
p413 | doi:10.1038/nrrheum.2009.133
http://links.ealert.nature.com/ctt?kn=92&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Connective tissue diseases: Selective targeting for SLE
p414 | doi:10.1038/nrrheum.2009.126
http://links.ealert.nature.com/ctt?kn=58&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
IN BRIEF
Connective tissue diseases | Spondyloarthropathies | Osteoimmunology |
Rheumatoid arthritis
p414 | doi:10.1038/nrrheum.2009.134
http://links.ealert.nature.com/ctt?kn=25&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Inflammation: Inflammation interference
p415 | doi:10.1038/nrrheum.2009.131
http://links.ealert.nature.com/ctt?kn=39&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
IN BRIEF
Connective tissue diseases | Vasculitis syndromes | Experimental arthritis
| Rheumatoid arthritis
p415 | doi:10.1038/nrrheum.2009.135
http://links.ealert.nature.com/ctt?kn=29&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Connective tissue diseases: Shedding light on SLE autoimmunity
p416 | doi:10.1038/nrrheum.2009.122
http://links.ealert.nature.com/ctt?kn=7&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Peptide modulates SLE gene expression
p416 | doi:10.1038/nrrheum.2009.127
http://links.ealert.nature.com/ctt?kn=93&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Osteoimmunology: Prevalence of hypovitaminosis D and relationship to fracture
Karen E. Hansen
p417 | doi:10.1038/nrrheum.2009.143
As of May 1, 2009, PubMed listed approximately 30,000 citations on the
topic of vitamin D in humans, highlighting the medical community's avid
interest in this field. Two articles published in the Archives of Internal
Medicine diverge with previous reports on the prevalence of hypovitaminosis
D and the capability of vitamin D to reduce fractures.
http://links.ealert.nature.com/ctt?kn=21&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Therapy: Targeted but not trouble-free: efalizumab and PML
Eamonn S. Molloy and Leonard H. Calabrese
p418 | doi:10.1038/nrrheum.2009.142
In April 2009, efalizumab was withdrawn from the market for the treatment
of psoriasis after reports emerged of an association between long-term
therapy and the development of progressive multifocal leukoencephalopathy
(PML). This event highlights an urgent need for greater awareness and
research into the screening, diagnosis and treatment of this potentially
fatal disease in patients undergoing immunosuppressive therapy for chronic
inflammatory disorders.
http://links.ealert.nature.com/ctt?kn=50&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Osteoimmunology: Wnt antagonists: for better or worse?
Rik J. Lories and Frank P. Luyten
p420 | doi:10.1038/nrrheum.2009.144
Molecules involved in developmental signaling pathways have emerged as
therapeutic targets for various rheumatic diseases. New research sheds
light on the consequences of interfering with these processes.
http://links.ealert.nature.com/ctt?kn=98&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Ethics: Privilege and principle: gifts and industry relationships revisited
Richard S. Panush
p421 | doi:10.1038/nrrheum.2009.145
Several high-profile institutions are now following the trend of limiting
doctors' ties to industry by way of implementing stringent new guidelines.
But do the recommendations go far enough?
http://links.ealert.nature.com/ctt?kn=48&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Therapy: Guidelines in rheumatology: quo vadis?
Arthur Kavanaugh
p423 | doi:10.1038/nrrheum.2009.146
The choice of optimum second-line DMARDs for patients with rheumatoid
arthritis is fraught with challenges. The implementation of evidence-based
guidelines designed to inform clinicians' decisions requires careful
consideration of several important issues.
http://links.ealert.nature.com/ctt?kn=96&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Approaches to the targeting of treatment for osteoporosis
John A. Kanis, Eugene V. McCloskey, Helena Johansson and Anders Oden
p425 | doi:10.1038/nrrheum.2009.139
New clinical guidelines incorporate the concept of absolute fracture risk,
an important advance in the field of rheumatology. This Review article
discusses the background, history and recent advances in the use of absolute
fracture risk assessment in the management of patients with osteoporosis.
Abstract: http://links.ealert.nature.com/ctt?kn=86&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=9&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
B-cell-directed therapies for autoimmune disease
Thomas Dorner, Andreas Radbruch and Gerd R. Burmester
Published online: 07 July 2009
p433 | doi:10.1038/nrrheum.2009.141
B-cell-directed therapies for autoimmune diseases have been the focus of
extensive research during the past few years. In this Review, the authors
discuss therapies that directly and indirectly target B cells. They outline
clinical experience to date, mechanisms of action at the cellular level
and possible issues of relevance to the efficacy and safety of these
therapeutics.
Abstract: http://links.ealert.nature.com/ctt?kn=59&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=62&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Wnt and PPAR[gamma] signaling in osteoblastogenesis and adipogenesis
Ichiro Takada, Alexander P. Kouzmenko and Shigeaki Kato
Published online: 07 July 2009
p442 | doi:10.1038/nrrheum.2009.137
The signaling pathways regulating the closely linked processes of
adipogenesis and osteoblastogenesis are controlled by numerous transcription
factors. This article focuses on the role of peroxisome proliferator
activated receptor [gamma] in the promotion of adipogenesis, and the
Wnt-[beta]-catenin and noncanonical Wnt signaling pathways in the promotion
of osteoblastogenesis, and the crosstalk between these pathways.
Abstract: http://links.ealert.nature.com/ctt?kn=81&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=15&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Sensors of the innate immune system: their mode of action
Roberto Baccala, Rosana Gonzalez-Quintial, Brian R. Lawson, Michael E. Stern,
Dwight H. Kono, Bruce Beutler and Argyrios N. Theofilopoulos
Published online: 14 July 2009
p448 | doi:10.1038/nrrheum.2009.136
A tripartite sensing apparatus, comprising Toll-like receptors, retinoid
acid-inducible gene-I-like receptors and other cytosolic nucleic acid
sensors, and nucleotide-binding and oligomerization domain-like receptors,
has evolved to bring about an immediate but short-lived defense response
to microbial pathogens and their products. The main components of these
three systems and their function in detecting cellular danger are outlined
in this article.
Abstract: http://links.ealert.nature.com/ctt?kn=23&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=16&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
A case of cervical spine meningioma following etanercept use in a patient
with RA
Omer N. Pamuk and Ferda Harmandar
p457 | doi:10.1038/nrrheum.2009.138
This Case Study presents a 70-year-old woman who was administered etanercept
to treat rheumatoid arthritis that was active, despite therapy with
conventional DMARDs. During follow-up, the patient's symptoms improved but
she developed weakness and numbness in her arms and legs. Investigations
revealed a mass in her cervical spine, which was histopathology confirmed
to be a benign meningioma.
Abstract: http://links.ealert.nature.com/ctt?kn=78&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=89&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Is rheumatoid arthritis really getting less severe?
Till Uhlig and Tore K. Kvien
p461 | doi:10.1038/nrrheum.2009.140
Since the 1970s, rheumatologists have increasingly reported seeing patients
with milder onset of rheumatoid arthritis and a less-severe disease course
than in preceding decades. Are these improvements attributable to earlier
diagnosis, better therapeutic options, or simply a milder natural disease
course? Uhlig and Kvien review the evidence for the perceived decrease
in disease severity and discuss the potential reasons for this phenomenon.
Abstract: http://links.ealert.nature.com/ctt?kn=72&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=52&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Making an impact in Immunology!
Nature Immunology Impact Factor: 25.113*
Nature Reviews Immunology Impact Factor: 30.006*
Nature Immunology and Nature Reviews Immunology maintain their position
as the number one primary research journal and monthly review journal in
immunology. Ensure you have access to the most cited papers in the field.
Subscribe to Nature Immunology at a 20% discount:
http://links.ealert.nature.com/ctt?kn=85&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Subscribe to Nature Reviews Immunology at a 20% discount:
http://links.ealert.nature.com/ctt?kn=88&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
Visit here to recommend to your library:
http://links.ealert.nature.com/ctt?kn=31&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
*2008 Journal Citation Reports (Thomson Reuters, 2009)
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=13&m=33785447&r=MTc2NDQ4MTc5OAS2&b=2&j=NTQ3MzE5NTIS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
